RxDoctor Payments Data

Paula Boyle, MD

Family Medicine · Young Harris, GANPI 1972506012

Payments from drug & device makers

$569in general payments, 2019–2025

Across 19 payments — averaging $29.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$147
  • AbbVie$119
  • Novo Nordisk$74
  • Exact Sciences$57
  • Sunovion Pharmaceuticals Inc.$49
  • Mylan Specialty L.p.$30
  • plus $92 from 6 others

What the payments were for

  • Food & beverage$569100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$569 in reported general payments places this provider in the 50th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$218,365
Medicare patients
949
Services billed
6,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$112,977
JardianceEmpagliflozin61$62,691
EliquisApixaban60$53,176
RybelsusSemaglutide27$49,996
TrulicityDulaglutide33$47,702
MounjaroTirzepatide46$46,327
Tresiba Flextouch U-200Insulin Degludec22$12,195
AbrysvoRsv Vacc, Pref A And Pref B/Pf35$11,126
FarxigaDapagliflozin Propanediol11$10,270
SynthroidLevothyroxine Sodium79$8,351
Diclofenac Sodium45$8,252
PremproEstrogen,con/M-Progest Acet11$7,942
ShingrixVaricella-Zoster Ge/As01b/Pf32$7,095
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$6,573
Levothyroxine Sodium571$5,141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$74$162,973128 claims
Boehringer IngelheimJardiance$14$62,69161 claims
AbbVieSynthroid, Viibryd$119$12,66691 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Young Harris

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →